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Statement of Translational Relevance  
 Signaling through the phosphoinositide 3 kinase/AKT/mammalian target of rapamycin 
(PI3K/AKT/mTOR) pathway has been implicated in angiogenesis and cell growth in several 
types of cancer. The PI3K axis is abnormally activated in most high grade gliomas. We 
developed an oral, brain-penetrant small molecule inhibitor of phosphoinositide 3-kinase (PI3K) 
and mammalian target of rapamycin (mTOR) as a therapy for patients with high-grade glioma, 
where genomic alterations in this pathway occur in a majority of patients. A multi-center Phase I 
first-in-human study of GDC-0084 was conducted in patients with high-grade glioma. This 
Phase I study showed that GDC-0084 has good PK properties and acceptable safety profile with 
signs of pharmacodynamic effects in the CNS, as evidenced by FDG-PET. Our data suggests that 
clinical investigation of GDC-0084 in patients with high grade glioma in earlier lines of therapy 
or with other rational combination partners is warranted.        
 
 
Abstract 
Purpose: GDC-0084 is an oral, brain-penetrant small molecule inhibitor of phosphoinositide 3-
kinase (PI3K) and mammalian target of rapamycin (mTOR). A first-in-human, Phase I study was 
conducted in patients with recurrent high-grade glioma.  
 
Experimental design: GDC-0084 was administered orally, once-daily to evaluate safety, 
pharmacokinetics (PK) and activity. Fluorodeoxyglucose positron emission tomography (FDG-
PET) was performed to measure metabolic responses.  
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Results: Forty-seven heavily pretreated patients enrolled in eight cohorts (2-65 mg). Dose-
limiting toxicities (DLTs) included one case of Grade 2 bradycardia and Grade 3 myocardial 
ischemia (15 mg), Grade 3 stomatitis (45 mg) and 2 cases of Grade 3 mucosal inflammation (65 
mg); the maximum tolerated dose (MTD) was 45 mg/day. GDC-0084 demonstrated linear and 
dose-proportional PK, with a half-life (~19 hr) supportive of once-daily dosing. At 45 mg/day, 
steady-state concentrations exceeded pre-clinical target concentrations producing antitumor 
activity in xenograft models. FDG-PET in 7 of 27 patients (26%) showed metabolic partial 
response. At /day, a trend towards decreased median SUV in normal brain was 
observed, suggesting central nervous system penetration of drug. In 2 resection specimens, 
GDC-0084 was detected at similar levels in tumor and brain tissue, with a brain tissue/tumor to 
plasma ratio of > 1 and > 0.5 for total and free drug, respectively. Best overall response was 
stable disease in 19 patients (40%), and progressive disease in 26 patients (55%); 2 patients (4%) 
were non-evaluable.  
 
Conclusions: GDC-0084 demonstrated classic PI3K/mTOR-inhibitor related toxicities. FDG-
PET and concentration data from brain tumor tissue suggest that GDC-0084 crossed the blood-
brain barrier. 
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Background 
 Glioblastoma is the most common primary brain tumor, accounting for 15% of all brain 
and central nervous system tumors and approximately 56% of all gliomas (1). Evidence of 
common genetic abnormalities in signal transduction pathways that control angiogenesis and cell 
growth and survival have led to the development of new treatments that target molecules in these 
signaling pathways. However, prognosis remains poor with current standard of care, with few 
patients surviving beyond 5 years (2-5). 
 Activation of the phosphoinositide 3 kinase/AKT/mammalian target of rapamycin 
(PI3K/AKT/mTOR) pathway has been implicated in angiogenesis (6,7) and cell growth (8) in 
several types of cancer (9-11),  80% of glioblastomas (12-15). Additionally, loss of 
phosphatase and tensin homolog (PTEN) expression or function, and dysregulation of receptor 
tyrosine kinases that exert downstream effects on PI3K are common in gliomas (16). Activating 
mutations in PIK3CA (the gene encoding the p110 catalytic subunit PI3K ) and mutations in 
PIK3R1 (the gene encoding the regulatory subunit p85) are also evident in gliomas (17).  
 GDC-0084 is a potent, oral, selective, brain-penetrant small molecule inhibitor of both 
phosphoinositide PI3K and mTOR kinase that was specifically designed for the treatment of 
brain cancer. GDC-0084 was designed to efficiently cross the blood brain barrier to achieve high 
drug exposure in the brain, thus maximizing its potential to treat brain cancers such as 
glioblastomas. In mouse xenograft models, GDC-0084 demonstrated dose-dependent tumor-
growth inhibition (TGI), with 60% and 90% TGI observed at clinically relevant exposures 
(18,19). 
 Together, these data provided the rationale for investigating GDC-0084 for the treatment 
of patients with progressive or recurrent high-grade glioma. The primary objectives of this study 
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were to assess the safety, tolerability, and pharmacokinetics (PK) of GDC-0084 in patients with 
progressive or recurrent high-grade gliomas (WHO Grade III IV), and to determine the 
maximum tolerated dose (MTD) of GDC-0084 and characterize the dose-limiting toxicities 
(DLTs). We also sought to characterize pharmacodynamic (PD) effects of GDC-0084 through 
assessment of change in glucose metabolism by means of 18F-Fluorodeoxyglucose positron 
emission tomography (FDG-PET) scans. Other objectives included a preliminary assessment of 
anti-tumor activity of GDC-0084. 
 
Patients and Methods 
Study design  
 This was an open-label, multicenter, Phase I, dose-escalation study using a standard 3+3 
design. GDC-0084 (supplied by Genentech, Inc.) was administered orally once-daily in cycles of 
28 days, on a continuous dosing schedule at doses of 2-65 mg. Dose escalation followed a 3+3 
design and continued until the MTD was exceeded, excessive pill burden was declared, or 
analysis of available PK data indicated that exposure was unlikely to increase with further 
increases in the dose of GDC-0084. The MTD was defined as the highest dose level at which < 
33% of patients develop a DLT during Cycle 1 Days 1-28.  
 DLTs were defined as any National Cancer Institute Common Terminology Criteria for 
Adverse Events (NCI CTCAE), version 4.0 -hematologic toxicity unrelated to 
hyperglycemia or hyperlipidemia and is not due to disease progression or another clearly 
identifiable causes (excluding alopecia, nausea, vomiting, diarrhea, or electrolyte imbalance not 
managed with standard-of-care therapy, or asymptomatic lipase or creatine phosphokinase 
abnormality). Other DLTs included Gr Grade 3 symptomatic 
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fasting hyperglycemia (e.g., dehydration or acidosis requiring hospitalization), Grade 3 
-hyperglycemic 
therapy, G
intervention with a lipid-lowering agent, Grade 4 thrombocytopenia, Grade 3 thrombocytopenia 
Grade 4 neutropenia 
 
 
Patients 
 with histologically documented high-grade gliomas 
(WHO Grade III IV, by local pathology review) , with recurrent or progressive disease as 
defined by the Response Assessment in Neuro-Oncology (RANO) Criteria (20), and prior 
treatment with 
III gliomas and radiotherapy with chemotherapy for Grade IV gliomas). Patients had be to 
weeks from completion of adjuvant radiotherapy for gliomas to study entry, and baseline brain 
MRI scan performed within 14 days prior to initiation of study drug while either not receiving 
glucocorticoids or on a stable dose of glucocorticoids during the 5 consecutive days prior to the 
scan. Patients had to have Karnofsky Performance Status (KPS) 
bone marrow function 
 1.5 × ULN), fasting plasma glucose less than 150 mg/dL, 
and QTc less than 500 milliseconds. 
 Patients were excluded if there was a history of prior treatment with a PI3K, mTOR, or 
ed or otherwise 
would be at increased risk for additional PI3K or mTOR related toxicity, anti-tumor therapy 
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within 4 weeks, requirement for chronic corticosteroid therapy consisting of  > 2 mg 
dexamethasone per day or an equivalent dose of other corticosteroids, G
hypercholesterolemia or hypertriglyceridemia, 
cardiovascular events or medical disorders, and treatment with enzyme-inducing anti-epileptic 
agents or warfarin. There were no molecular eligibility criteria.  
 The study protocol was approved by local Institutional Review Boards prior to patient 
recruitment and was conducted in accordance with the Declaration of Helsinki International 
Conference on Harmonization E6 Guidelines for Good Clinical Practice. Written informed 
consent was obtained for all patients prior to performing study-related procedures in accordance 
with federal and institutional guidelines. The study was registered on ClinicalTrials.gov 
(NCT01547546). 
 
Safety assessments 
 Safety assessments were determined weekly during Cycle 1 and then every 2 
weeks thereafter using NCI CTCAE v4.0. Cycle 1 was the DLT assessment window. 
 
Pharmacokinetic assessments 
 Frequent blood samples for PK analysis were collected on Days 1 and 8, or Day 15 of 
Cycle 1. A validated liquid chromatographic-tandem mass spectrometry (LC/MS-MS) method 
n of GDC-
0084 in plasma samples. PK parameters were estimated using non-compartmental analysis 
(Phoenix WinNonlin 6.4; Cetara, Princeton, NJ).  
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Brain penetration 
 Brain-to-plasma ratios were estimated from two patients (post hoc analysis and not from 
a pre-specified cohort). Tumor, adjacent brain tissue and plasma samples from one patient were 
obtained ~5.5 hr (plasma) and 7 hr (brain) after 45 mg QD dosing to steady-state.  Post-mortem 
tumor and brain samples were collected from another patient taking 45 mg QD (last dose was 11 
days prior to death) and plasma concentrations at the time of death were estimated using this 
-life. GDC-0084 in plasma and brain samples were measured 
using LC/MS-MS.  
 
Activity outcomes 
 Disease status was assessed using RANO criteria for high-grade gliomas (20) at 
screening, on Day 1 of Cycle 2, every 8 weeks  
of a complete or partial response (all +/- 7 days). Time on study was defined as time from first 
GDC-0084 dose to study discontinuation.  
 
Biomarker assessments 
 To demonstrate the ability of GDC-0084 to exert biologic effects in tumor tissue and aid 
in the dose selection, FDG-PET was performed at baseline and on-treatment either on Day 1 of 
Cycle 2 (+7 days), or Day 8 of Cycle 1 (+ 7 days), within 1-4 hours of dosing. In general, patient 
preparation and FDG-PET data acquisition procedures followed guidelines by the National 
Cancer Institute (21,22). Reconstructed FDG-PET images were converted into standardized 
uptake value (SUV) maps. Regions of interest (ROIs) were delineated for each MRI enhancing 
lesion and the maximum SUV (SUVmax) within each ROI was computed. The percent change on 
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the average SUVmax across all patient lesions was used as quantitative measure of treatment 
effect on disease metabolic activity. A decrease in disease metabolic activity of at least 20% 
constituted a partial metabolic response. Median SUV in non-enhancing brain tissue was also 
computed as a measure of metabolic activity in normal brain.  
 Pre-treatment tumor tissue, when available, was profiled for PTEN expression using 
immunohistochemical methods, as previously described (23), and using a targeted next 
generation sequencing gene panel, as previously described (24). O6-methylguanine-DNA 
methyltransferase status was not formally assessed as part of the study. 
 
Statistical methods 
 A 3+3 dose escalation design was used to determine the MTD. No formal statistical 
hypotheses were tested in this study. Design considerations were not made with regard to explicit 
power and type I error, but to obtain preliminary safety, PK, and PD information. For the safety 
analysis and the activity analysis, all patients -0084 were 
included. Descriptive statistics were used throughout the study.  
 
Data sharing 
 Qualified researchers may request access to individual patient level data through the 
clinical study data request platform (www.clinicalstudydatarequest.com). Further details on 
Roche's criteria for eligible studies are available here 
(https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further 
details on Roche's Global Policy on the Sharing of Clinical Information and how to request 
access to related clinical study documents, see here 
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(https://www.roche.com/research_and_development/who_we_are_how_we_work/ 
clinical_trials/our_commitment_to_data_sharing.htm) 
 
Results 
Patient characteristics 
 Forty-seven patients were enrolled in 8 successive dose escalation cohorts (2-65 mg GDC-
0084). The baseline characteristics of the patient population are shown in Table 1. The median 
age was 50 years (range 29-73) with more males (72%) enrolled than females. At study 
enrollment 14 patients (30%) were classified as WHO Grade III glioma and 33 patients (70%) 
were classified as WHO Grade IV glioma. Median KPS was 90 (range of 70-100). The mean 
number of prior systemic therapies was 3 (range 1-5), and 23 patients (48%) received 
bevacizumab in the immediate prior line of therapy. 
 
Safety, tolerability, and adverse events 
 The most frequent AEs attributed to GDC-0084 were fatigue, hyperglycemia, nausea, 
rash, hypertriglyceridemia, mucositis, hypophosphatemia, decreased appetite, and diarrhea 
(Table 2). Nine patients (19%) experienced Grade 3 AEs related to GDC-0084, including 
hyperglycemia (4 patients [9%]) and mucositis (3 patients [6%]).  
 Overall, 4 patients experienced DLTs in this study. In the 15 mg dose group, 1 patient 
experienced Grade 2 bradycardia and Grade 3 myocardial ischemia. In the 45 mg dose group, 
1 of 8 patients experienced Grade 3 stomatitis. In the 65 mg dose group, 2 of 6 patients 
experienced Grade 3 mucosal inflammation. All DLTs were considered related to GDC-0084. 
The MTD was determined to be 45 mg GDC-0084 given orally once-daily in 28 day cycles.  
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 Seven of 47 patients (15%) experienced serious AEs (SAEs) related to GDC-0084. Five 
patients (11%) reported Grade 3 SAEs related to GDC-0084 (dry skin, fatigue, hyperglycemia, 
myocardial ischaemia, pneumocystis jirovecii pneumonia, pruritus, and stomatitis). There were 
no SAEs related to GDC-0084 that were higher than Grade 3. 
 Six patients (13%) experienced AEs that led to dose reduction or dose discontinuation of 
GDC-0084. Three patients (6%) experienced mucositis and all other AEs leading to dose 
reduction or dose discontinuation were reported by 1 patient at most. 
 Seven patients (15%) experienced GDC-0084-related AEs of special interest; 4 patients 
(9%) experienced hyperglycemia, 3 patients (6%) experienced mucositis and 1 patient each (2%) 
experienced bradycardia, myocardial ischaemia, and pruritus. One death was reported in this trial 
due to disease progression, which was deemed not related to GDC-0084.  
 
Pharmacokinetic analysis 
 PK analyses using plasma samples GDC-0084 was rapidly absorbed (Tmax ~2 hours) and 
displayed an approximately linear and dose proportional increase in Cmax and AUC0-24, with a 
half-life of ~18.7 hours, which is supportive of once-daily dosing (Figure 1A). The accumulation 
ratio had a mean value of 2.1 ± 0.9, which was consistent with the theoretical accumulation 
based upon half-life estimates and the once-daily dosing interval. Exposure of GDC-0084 
observed at the MTD of 45 mg QD exceeds the pre-clinically predicted exposure associated with 
efficacy (60% TGI) in 7 of 8 patients (Figure 1B). 
 
Brain penetration 
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 In surgical and post-mortem samples from two patients dosed at 45 mg QD, GDC-0084 
was detected at similar levels in brain tumor and tissue (surgical samples: 0.80 uM [tumor], 0.86 
uM [brain]; post-mortem: 1.79 nM [tumor], 0.97 nM [brain]). In the surgical samples, the brain 
tumor to plasma and brain tissue to plasma ratios were >1.43 and >1.54 for total drug and >0.48 
and >0.51 for free drug, respectively. In the post-mortem samples the brain tumor to plasma and 
brain tissue to plasma ratios were estimated to be ~1.1 and ~0.6 for total drug and ~0.60 and 
~0.21 for free drug, respectively.  
 
Clinical activity 
 Of the patients with evaluable FDG-PET data, 7 of 27 (26%) patients had a metabolic 
partial response (Figure 2). 
normal brain was observed, suggesting CNS penetration of study drug. 
 Overall in this heavily pretreated population, no objective response as assessed by RANO 
criteria were observed (Figure 3), and best response was limited to stable disease in 19 patients 
(40%) in the 2, 4, 8, 15, 45, and 65 mg cohorts. Twenty-six patients (55%) had progressive 
disease. Two patients (4%) did not have evaluable post-treatment response assessment. Three 
patients (6%) stayed on study for at least 6 months (Figure 4). 
 
Biomarker analysis 
 PTEN tissue expression was assessed in 36 patients (Figure 3). Overall, 20 patients had 
PTEN loss and/or a PIK3CA mutation. Complete loss of PTEN protein was observed in 1 patient 
and low expression was observed in 15 patients (42%). Normal PTEN expression was observed 
in 20 patients with no data available for 11 patients.  
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 A targeted next generation sequencing panel was run on patients with remaining tissue. 
Twenty-two patients had sufficient tissue that passed quality control that generated somatic 
mutation results. Seven PTEN mutations were identified, one of which had complete loss of 
PTEN protein expression, 2 had low PTEN expression and 4 had normal PTEN expression. Six 
PIK3CA mutations were identified in the tumor samples, 4 of which were hotspot mutations 
(E542K, E545G and H1047R) and 2 were non-hotspot mutations (S774F and R949Q).  
 Two patients were identified as PIK3CA mutant by the local test. One activating AKT1 
mutation (E17K) and 1 non-spot mutation (D32G) were identified. Seven unique mutations in 
the PI3K regulatory domain, PIK3R2, were also identified. Finally, 1 EGFR single nucleotide 
variant mutation and 1 deletion mutation were found in tumor samples from 2 patients (E829K 
and V592del). There was no clear correlation between the genomic status of the tumor and 
outcomes in this Phase I study. 
 
Discussion 
In this first-in-human Phase I study of GDC-0084 in a population of heavily pretreated 
patients with recurrent high-grade gliomas the reported AEs were generally consistent with the 
established PI3K-mTOR inhibitor class effects. Mucositis was the predominant dose-limiting 
toxicity. The MTD of GDC-0084 was determined to be 45 mg/day with 1 of 8 patients 
experiencing a DLT  At this dose 7 of 8 patients had drug exposures consistent with 
anti-tumor activity in pre-clinical models. GDC-0084 was rapidly absorbed and demonstrated 
linear- and dose-proportional increases in exposure, with a half-life supportive of once-daily 
dosing. Although data was limited, drug concentrations obtained from one patient who 
underwent resection of recurrent tumor while receiving GDC-0084, and another patient whose 
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post-mortem brain was available for analysis, suggested that GDC-0084 crossed the blood brain 
barrier, with a brain tumor to plasma and brain to plasma ratios in excess of 1. Data from the 
FDG-PET studies showing a metabolic partial response in 26% of evaluated patients, and a trend 
towards decreased median SUV in normal brain at doses  also supported CNS 
penetration of GDC-0084. Though the PET studies were exploratory, the results are interesting 
and suggest a dose responsiveness to GDC-0084. Unlike other PI3K inhibitors that cross the 
blood-brain barrier such as buparlisib (25), there were no neuropsychiatric complications. This 
suggests that these previously reported toxicities were not a class effect of brain penetrant PI3K 
inhibitors, but more likely related specifically to buparlisib.  
 In this heavily pretreated unselected patient population in which patients had a median of 
3 prior therapies and 48% of patients received bevacizumab in the immediate prior line of 
therapy, the single-agent anti-tumor activity was limited. Fifty-five percent of patients 
demonstrated a best response of progressive disease and 40% of patients had stable disease. Two 
patients did not have evaluable post-treatment response assessment. It is possible the GDC-0084 
may have more activity in a less heavily pretreated population or in the first-line setting where 
the tumors may be less mutated and heterogenous. 
 To evaluate whether patients with PI3K pathway activation had a better outcome, tissue 
was obtained from a subset of patients to determine PTEN expression and the presence of PI3K 
mutations. Only 36 of 47 patients had tissue available for analysis of PTEN expression and 22 of 
47 patients had tissue of adequate quality for somatic mutational analysis. There was no clear 
correlation between PTEN loss or PI3K mutations and response to GDC-0084. However, since 
the tissues were usually obtained from the initial surgery, and not surgery following the most 
recent recurrence, it is unclear whether the molecular alterations that were determined accurately 
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reflected the situation in the tumor at the time the patients received GDC-0084. The lack of 
correlation of efficacy to PIK3CA status is similar to mTOR inhibitors in breast cancer. 
Everolimus activity in the breast cancer patient population is not linked to alterations in gene 
expression or signaling  pathways in HR+ HER2- tumors, or PIK3CA/WT mutation status 
(26,27).  
 Despite the importance of the PI3K-mTOR pathway in glioblastoma (15), there have been 
a paucity of agents inhibiting this pathway that adequately crosses the blood-brain barrier. 
Cloughesy et al  (28) administered voxtalisib (XL765), a pan PI3K/mTOR inhibitor or XL147, a 
pan PI3K inhibitor, to patients with recurrent glioblastoma and showed that voxtalisib had better 
tumor penetration than XL147, although both drugs produced significant reduction of pS6K1 
compared to archived tumor and reduction of Ki-67, suggesting that some inhibition of the PI3K 
pathway was achieved. Wen et al (29) subsequently conducted a Phase I trial of voxtalisib with 
temozolomide, with or without radiation therapy in patients with high-grade gliomas. The MTD 
was 90 mg once daily or 40 mg twice daily. However, drug development was suspended and 
additional studies were not performed. Kaley et al (30) evaluated perifosine, an AKT inhibitor, in 
a Phase II trial involving 16 GBM and 14 anaplastic astrocytoma patients. The agent was 
reasonably well tolerated but showed no efficacy in the GBM cohort with no responses, PFS6 of 
0% and a median survival of 3.68 months. One patient with anaplastic astrocytoma had a partial 
response.  
 Pitz et al reported aPhase III trial of a brain penetrant PI3K inhibitor PX-366 in 33 
unselected glioblastoma patients (31). The  agent was fairly well-tolerated but there was only 1 
(3%) partial response and 8 (24%) patients had stable disease. The 6 month progression free 
survival was 18%. Only a minority of patients had adequate tissue for evaluation of molecular 
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biomarkers and n
PTEN status, EGFRvIII mutation, PIK3CA mutation status or PIK3R1 mutation status. The study 
did not confirm whether therapeutic concentrations of the drug were achieved in the tumor or 
whether the PI3K pathway was inhibited. More recently, Wen et al reported that the pan-PI3K 
inhibitor buparlisib crossed the blood brain barrier well with tumor-to-plasma patios in excess of 
1, but the drug failed to inhibit the PI3K pathway adequately (25). At the recommended Phase II 
dose of 100 mg daily, buparlisib inhibited phosphorylated AKTS473 in 6 of 14 patients (43%), but 
had no effect on phosphoribosomal protein S6S235/236 or tumor proliferation. This was reflected in 
the lack of clinical activity of the drug with no responders and a 6 month PFS of only 8%. It 
therefore remains unknown whether a PI3K inhibitor that can cross the blood brain barrier and 
adequately inhibit the pathway will have activity or whether the heterogeneity of the tumor and 
the presence of redundant pathways will require combination therapies. 
 There have also been a number of prior studies of mTOR inhibitors in recurrent 
glioblastoma (231-35). Most of the trials that have been reported targeted mTORC1 and were 
ineffective, possibly because of incomplete inhibition of mTORC1, and release of mTORC1-
mediated restraints on PI3K/mTORC2/AKT signaling, resulting in resurgent AKT signaling 
(36,37). Agents that target both mTORC1 and 2, such as GDC-0084, are potentially more 
effective and studies with these agents in glioblastoma are ongoing. It is possible that by 
inhibiting both PI3K and mTOR, GDC-0084 will inhibit the PI3K pathway more effectively than 
agents inhibiting only one of these targets. 
 In summary, GDC-0084 is reasonably well-tolerated at 45 mg daily, a dose which 
exceeds the pre-clinically predicted exposure associated with efficacy and appears to cross the 
blood brain barrier. These data support further development of GDC-0084. The exploration of 
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rational GDC-0084 combinations in patient-derived glioblastoma organoid models may be of 
value (38, 39). This agent is being evaluated in a Phase I/II trial in patients with newly-diagnosed 
glioblastoma with unmethylated DNA-methylguanine- methyltransferase promoter status as 
adjuvant therapy following surgical resection and initial chemoradiation with temozolomide 
(NCT03522298), and in Phase II trials in diffuse intrinsic pontine glioma and diffuse midline 
gliomas (NCT03696355), HER2 positive breast cancer brain metastases (NCT03765983) and 
brain metastases with PI3K pathway activation (NCT03994796). 
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Table 1. Patient demographics and disease characteristics.  
 
Characteristic 2 mg (n=7) 
4 mg 
(n=4) 
8 mg 
(n=5) 
15 mg 
(n=6) 
20 mg 
(n=4) 
30 mg 
(n=7) 
45 mg 
(n=8) 
65 mg 
(n=6) 
All Patients  
(N=47) 
Age in years, median 
(range) 58 (32 63) 61 (30 64) 44 (38 59) 57 (38 62) 38 (30 50) 56 (44 73) 49 (31-62) 42 (29 59) 50 (29 73) 
Sex (male) 5 (71%) 3 (75%) 5 (100%) 4 (67%) 2 (50%) 3 (43%) 6 (75%) 6 (100%) 34 (72%) 
Time from primary 
diagnosis (mo.), median 
(range) 
56 (13 182) 37 (22 47) 53 (22 67) 43 (14 87) 24 (18 132) 20 (11 45) 97 (23 190) 35 (12 100) 41 (11 190) 
No. prior systemic 
therapies, median (range) 4 (1-4) 3.5 (2-5) 3 (1-5) 3.5 (1-5) 2 (2-3) 3 (2-5) 3 (2-5) 3 (2-4) 3 (1-5) 
WHO Grade 
     III 
     IV 
 
3 (43%) 
4 (57%) 
 
1 (25%) 
3 (75%) 
 
1 (20%) 
4 (80%) 
 
1 (17%) 
5 (83%) 
 
1 (25%) 
3 (75%) 
 
- 
7 (100%) 
 
5 (63%) 
3 (38%) 
 
2 (33%) 
4 (67%) 
 
14 (30%) 
33 (70%) 
Baseline KPS scale score 
     70 
     80 
     90 
     100 
 
1 (14%) 
4 (57%) 
2 (29%) 
- 
 
- 
1 (25%) 
3 (75%) 
- 
 
1 (20%) 
1 (20%) 
3 (60%) 
- 
 
- 
1 (17%) 
5 (83%) 
- 
 
1 (25%) 
1 (25%) 
2 (50%) 
- 
 
2 (29%) 
3 (43%) 
2 (29%) 
- 
 
3 (38%) 
- 
4 (50%) 
1 (13%) 
 
1 (17%) 
2 (33%) 
3 (50%) 
- 
 
9 (19%) 
13 (28%) 
24 (51%) 
1 (2%) 
WHO=World Health Organization; KPS=Karnofski Performance Status.  
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Table 2. Adverse events related to GDC-0084 o patients.  
 
 2 mg (n=7) 
4 mg 
(n=4) 
8 mg 
(n=5) 
15 mg 
(n=6) 
20 mg 
(n=4) 
30 mg 
(n=7) 
45 mg 
(n=8) 
65 mg 
(n=6) 
All Patients  
(N=47) 
 
Grad
e 3 
All 
Grade 
Grad
e 3 
All 
Grade 
Grad
e 3 
All 
Grade 
Grad
e 3 
All 
Grade 
Grad
e 3 
All 
Grade 
Grad
e 3 
All 
Grade 
Grad
e 3 
All 
Grade 
Grad
e 3 
All 
Grade 
Grad
e 3 
All 
Grade 
Any adverse 
events 0 
1 
(14%) 0 
3 
(75%) 0 
3 
(60%) 
1 
(17%
) 
4 
(67%) 0 
4 
(100%
) 
2 
(29%
) 
6 
(86%) 
2 
(25%
) 
7 
(88%) 
4 
(67%
) 
5 
(83%) 
9 
(19%
) 
33 
(70%) 
Fatigue a 0 0 0 0 0 1 (20%) 0 
2 
(33%) 0 
1 
(25%) 
1 
(14%
) 
2 
(29%) 0 
5 
(62%) 0 
3 
(50%) 
1 
(2%) 
14 
(30%) 
Hyperglycemia 0 0 0 1 (25%) 0 
1 
(20%) 
1 
(17%
) 
3 
(50%) 0 0 
1 
(14%
) 
3 
(43%) 0 
2 
(25%) 
2 
(33%
) 
3 
(50%) 
4 
(9%) 
13 
(28%) 
Nausea 0 0 0 2 (50%) 0 
1 
(20%) 0 0 0 
3 
(75%) 0 
1 
(14%) 0 
2 
(25%) 0 
2 
(33%) 0 
11 
(23%) 
Rash b 0 0 0 0 0 0 0 0 0 0 0 0 0 3 (38%) 0 
5 
(83%) 0 
8 
(17%) 
Hypertriglycerid
emia 0 0 0 
1 
(25%) 0 0 0 
1 
(17%) 0 0 0 
2 
(29%) 0 
2 
(25%) 0 
1 
(17%) 0 
7 
(15%) 
Mucositis c 0 0 0 0 0 0 0 0 0 0 0 0 
1 
(12%
) 
4 
(50%) 
2 
(33%
) 
3 
(50%) 
3 
(6%) 
7 
(15%) 
Hypophosphate
mia 0 0 0 
1 
(25%) 0 
2 
(40%) 0 0 0 0 0 0 0 
2 
(25%) 
1 
(17%
) 
1 
(17%) 
1 
(2%) 
6 
(13%) 
Decreased 
appetite 0 0 0 0 0 0 0 0 0 
1 
(25%) 0 0 0 
4 
(50%) 0 0 0 
5 
(11%) 
Diarrhea 0 0 0 1 (25%) 0 0 0 0 0 0 0 
1 
(14%) 0 
1 
(12%) 0 
2 
(33%) 0 
5 
(11%) 
Vomiting 0 0 0 0 0 0 0 0 0 2 (50%) 0 0 0 
1 
(12%) 0 
1 
(17%) 0 4 (9%) 
Cholesterol 
increased 0 0 0 0 0 0 0 0 0 0 0 
2 
(29%) 0 
1 
(12%) 0 0 0 3 (6%) 
Hypercholestero
lemia 0 0 0 
1 
(25%) 0 0 0 
1 
(17%) 0 0 0 0 0 0 0 
1 
(17%) 0 3 (6%) 
Platelet count 
decreased 0 0 0 0 0 0 0 0 0 0 0 0 0 
2 
(25%) 0 
1 
(17%) 0 3 (6%) 
No Grade 4 or 5 drug-related AEs were reported. a Fatigue includes fatigue and asthenia. b Rash includes rash and rash maculo-paular. c Mucositis includes mucosal inflammation 
and stomatitis. 
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Figure Legends 
 
Figure 1. GDC-0084 pharmacokinetics. (A) Mean (± SD) steady-state plasma concentrations of 
GDC-0084 (B) Observed individual steady-state area under the curve (AUC0-24) values by dose 
level. Horizontal lines indicate exposures that correlate to percent tumor growth inhibition (TGI) 
exposure targets from a U87 (PTEN null) subcutaneous xenograft model (40).  
 
Figure 2. FDG-PET assessments. (A) change in mean standard update value (SUVmax) in tumor, 
and (B) median SUV in normal brain. IHC=immunohistochemistry; WT=wild type; 
MUT=mutant; ND=not detected, MUT* = local assessment. 
 
Figure 3. Objective response estimated for patients with disease measurable by response 
assessment in neuro-oncology criteria (RANO) guidelines. SPD=sum of products of diameters; 
PD=progressive disease; SD=stable disease; PR=partial response; IHC=immunohistochemistry; 
WT=wild type; MUT=mutant; ND=not detected; MUT* = local assessment. Best change in sum 
of product of diameters of target lesions is displayed by dose level. 
 
Figure 4. GDC-0084 time on study. Patients are grouped by dose levels. WHO glioma Grade (III 
or IV) is noted for each patient. 
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